DrMaria Prencipe

Prostate and breast cancer are the most common invasive cancers in the western world. Despite recent improvements in the therapeutic options available to patients, current therapeutic strategies for triple negative breast cancer and metastatic prostate cancer fail due to metastasis and development of resistance leading to high mortality rates. In this setting identifying novel therapeutic strategies and companion diagnostics is crucially important. My studies combine in vitro techniques (necessary to understand the molecular mechanisms behind resistance) with robust patient validation. This integrated translational approach will contribute to the better understanding of the mechanisms of anti-AR therapy resistance in the clinical setting, leading to better and more efficient therapies in both breast and prostate cancer. Importantly, the availability of small-molecule inhibitors for our targets of interest can potentially lead to rapid translation into the clinic.